Proportion of cancer biomarker testing done with NGS expected to double in 2022 compared to 2019

Across Europe, there are varying levels of laboratory infrastructure capacity supporting NGS testing and integration of NGS testing in cancer care.

Next-generation sequencing (NGS) in cancer biomarker testing: Testing trends in Europe labs

Europe’s cancer burden is increasing, with more patients undergoing biomarker testing in order to access more targeted and effective therapies. Economist Intelligence
Clearstate expects the number of patients undergoing routine molecular testing for cancer biomarkers tracked by IVD Gateway to grow at an average annual rate between 6.2 to 19.2% in EU5 countries from 2020 to 2025.

Cardiac and vascular surgery devices such as pacemakers, implantable cardioverter defibrillators (ICDs), heart valves, balloons, catheters, stents play a key role in managing and treating cardiovascular diseases. With an ageing population and the rising prevalence of cardiovascular diseases, technologies are being developed to treat patients more efficiently and less invasively using minimally invasive surgery (MIS) techniques and robotics.

Clearstate offers market data, forecasts, and trend predictions to give you the insight to adjust your business strategy to meet the growing opportunities in cardiac and vascular surgery.

Minimally invasive surgery (MIS) is done through smaller incisions compared with traditional open surgery, bringing about shorter recovery time and reduced risks and complications. With advancements in MIS techniques and devices, MIS adoption is expanding in many surgical specialties including orthopaedic surgery for hip and knee replacements and in cardiac surgery for coronary artery bypass surgery (CABG) and valvular surgery. There is growing demand for endoscopic or MIS devices and platforms and surgical technologies such as robotic-assisted surgical systems that can help surgeons perform more precise and less invasive procedures.

The choice for traditional open surgery is becoming less popular as Latin America (LATAM) speeds up its adoption of minimally invasive surgery (MIS) techniques.
Discover four areas where MIS medical devices are fast-transforming surgical procedures with Clearstate’s latest infographic.

Track IVD market size, share and trends with IVD Size & Share Plus by Clearstate

Lab by lab profiles of centralised diagnostics (CEDx) labs, molecular diagnostics labs (MDx) and tissue diagnostics (TDx) labs across hospitals and commercial settings to help your business understand current test, instrument and reagent usage of target customers.

What is next-generation sequencing (NGS)?

Next-generation sequencing (NGS) is a high-throughput method used to obtain the sequence of nucleotides in entire genomes or specific gene regions.

Clearstate provides an understanding of the progression and likely impact of covid-19 on the healthcare and IVD sector, enabling you to effectively plan ahead.

Europe is shifting its covid-19-approach from pandemic to endemic. The subsequent changes in government policy and the requirements for covid-19 surveillance and screening programmes will impact both test volume and the types of test technologies that will be frequently used.

Tissue diagnostics (TDx), also known as histology or anatomical pathology, uses various techniques to diagnose diseases based on tissues from organs and tumours. Advancements such as tissue-based companion diagnostics, automation and the use of digital solutions at laboratories are driving greater efficiency of TDx testing in critical areas such as cancer diagnosis and treatment planning.

The next-generation sequencing (NGS) market is expected to be APAC’s fastest-growing in-vitro diagnostics segment between now and 2025. More healthcare providers are recognising the significant advantages of this technology for prenatal testing and cancer diagnosis, which is driving widespread NGS adoption in the region and creating opportunities for IVD company growth.